IL18 and cancer: In contrast, with a higher dose of RP116 (MOI of 100) and IL-18/-21-pretreated eNK cells (E:T ratio of 1:1), the combination treatment showed low cancer cell viability (14% in HT-1376, 6% in 253J-BV) (Fig. 5B).